Most biotech companies are too risky to even think about holding forever. Between the big risk of a clinical trial blowing up and the lesser risk of getting one-upped by a competitor's medicine even after successfully moving a drug from the lab to the market, it's incredibly difficult to feel confident in a biotech's long-term future.

There are, however, a couple of exceptions to that trend. Let's take a look at two that are ready for a purchase and long-term hold today.

Image source: Getty Images.

Continue reading

Source Fool.com